Cardiometabolic & kidney

Feasibility and Prognostic Value of Stress Cardiovascular Magnetic Resonance in Patients With End-Stage Renal Disease

JACC AdvPublished observational single-center cohort study

Authors' conclusion

In ESRD patients, stress CMR is feasible, safe, and adds significant prognostic value for MACE beyond traditional risk factors by characterizing patterns of microvascular and macrovascular disease.

Study context

Population
Asymptomatic patients with end-stage renal disease (ESRD) (estimated glomerular filtration rate <30 mL/min/1.73 m² or on dialysis) on waitlist for kidney transplantation, referred for stress cardiovascular magnetic resonance (CMR)included of 3328 ESRD patients, age 60 years [53–66], 67% men, median follow-up 5.4 years
Participants
845 patients
Exposure
Stress CMR findings and major adverse cardiovascular events (MACE)

Main finding

As reported in the abstract

Major CMR-related adverse events
  • No major CMR-related adverse events occurred

Observational data: associations, not effects.

Further findings

MACE by abnormal perfusion and late gadolinium enhancement · median follow-up of 5.4 years

ComparisonaHR (95% CI)P value
Abnormal perfusion4.76 (3.34–6.79)P < 0.001
Presence of late gadolinium enhancement3.86 (2.59–5.74)P < 0.001

MACE by typical and atypical ischemic heart disease patterns

ComparisonaHR (95% CI)P value
Typical ischemic heart disease pattern5.68 (3.39–9.52)P < 0.001
Atypical ischemic heart disease pattern5.84 (3.82–8.91)P < 0.001
  • MACE by abnormal perfusion and late gadolinium enhancement: abnormal perfusion (12%); independent of traditional risk factors including prior coronary disease
  • MACE by abnormal perfusion and late gadolinium enhancement: late gadolinium enhancement (22%); independent of traditional risk factors including prior coronary disease

Prognostic accuracy beyond American Heart Association 2012 risk criteria for ESRD patients

C-statistic improvement
0.10

Original publication

Feasibility and Prognostic Value of Stress Cardiovascular Magnetic Resonance in Patients With End-Stage Renal Disease. JACC Adv. Published 28 July 2025. doi:10.1016/j.jacadv.2025.102008

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.